Loading
A phase 2 trial of Selinexor, Dexamethasone, Bortezomib in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. is a phase 2 interventional study registered as NCT04414475 by Karyopharm Therapeutics Inc, with 127 participants planned, started 2020-07-01 and due to reach its primary completion in 2028-01. Interventions recorded: Selinexor, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Karyopharm Therapeutics, Selinexor, Bortezomib, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/